- Analysis
- Barani Krishnan
- 19
Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
Metrics to compare | GABAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGABATPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −4.8x | −0.6x | |
PEG Ratio | −0.02 | −0.13 | 0.00 | |
Price/Book | −1.3x | 4.2x | 2.6x | |
Price / LTM Sales | - | 15.6x | 3.1x | |
Upside (Analyst Target) | - | 69.2% | 48.8% | |
Fair Value Upside | Unlock | −5.0% | 7.5% | Unlock |